• LAST PRICE
    4.2300
  • TODAY'S CHANGE (%)
    Trending Up0.0800 (1.9277%)
  • Bid / Lots
    4.0300/ 1
  • Ask / Lots
    4.5600/ 1
  • Open / Previous Close
    4.1300 / 4.1500
  • Day Range
    Low 4.0600
    High 4.2400
  • 52 Week Range
    Low 3.4900
    High 7.6000
  • Volume
    276,784
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 4.15
TimeVolumeMGTX
09:32 ET2424.13
09:34 ET55004.1001
09:36 ET2004.115
09:38 ET14304.13
09:39 ET1004.125
09:41 ET257484.11
09:43 ET55374.11
09:45 ET5284.1
09:52 ET8324.16
09:54 ET3004.14
09:56 ET22504.095
09:57 ET6004.0903
09:59 ET37004.08
10:06 ET511924.1
10:08 ET1004.115
10:10 ET1004.1
10:14 ET23284.17
10:17 ET2404.165
10:21 ET1004.165
10:24 ET5004.15
10:28 ET2004.165
10:30 ET9004.15
10:32 ET2004.15
10:33 ET1004.16
10:35 ET1004.16
10:39 ET1004.17
10:42 ET12424.17
10:44 ET3004.17
10:46 ET2174.17
10:50 ET3004.18
10:51 ET38914.23
10:53 ET10504.19
10:55 ET1004.19
11:02 ET1004.205
11:04 ET1004.23
11:08 ET1004.24
11:09 ET8004.225
11:15 ET4004.21
11:20 ET1004.22
11:24 ET1004.22
11:26 ET15324.21
11:27 ET2004.195
11:36 ET5044.2
11:38 ET2004.21
11:40 ET2004.22
11:42 ET2004.23
11:44 ET14064.23
11:47 ET5004.22
11:51 ET3004.22
11:58 ET3004.23
12:00 ET14894.22
12:02 ET1004.21
12:14 ET4004.225
12:16 ET9584.22
12:18 ET24564.18
12:23 ET3004.18
12:25 ET2004.19
12:30 ET1004.1999
12:32 ET2004.199
12:34 ET8004.19
12:36 ET7044.19
12:38 ET3004.18
12:39 ET4064.18
12:41 ET2004.175
12:45 ET6614.165
12:52 ET5134.18
12:56 ET1004.18
12:59 ET14004.17
01:01 ET2444.17
01:03 ET3004.17
01:06 ET1004.15
01:14 ET1004.15
01:15 ET3004.16
01:17 ET3004.16
01:21 ET5064.18
01:24 ET7894.17
01:26 ET3004.1755
01:32 ET1004.18
01:35 ET16484.155
01:37 ET3004.16
01:46 ET7364.17
01:48 ET1004.17
01:51 ET2004.18
01:53 ET2004.2
01:55 ET3004.205
01:57 ET15164.2
02:06 ET3004.2
02:08 ET8004.195
02:09 ET2344.19
02:18 ET1004.205
02:22 ET1014.2
02:24 ET3844.215
02:26 ET3004.22
02:27 ET4354.22
02:29 ET19014.2
02:33 ET3334.205
02:42 ET1004.22
02:44 ET1004.22
02:45 ET1004.23
02:47 ET1004.23
02:49 ET3224.23
02:51 ET2004.23
02:54 ET2004.24
02:56 ET23754.2
03:00 ET5004.2
03:03 ET1004.195
03:05 ET1004.2
03:07 ET1004.205
03:09 ET13264.2
03:14 ET1004.195
03:16 ET16554.18
03:21 ET2004.18
03:25 ET2004.19
03:27 ET1004.19
03:30 ET4444.2
03:32 ET23344.21
03:34 ET36384.2
03:36 ET1004.2
03:38 ET1004.205
03:41 ET2004.21
03:43 ET30804.21
03:45 ET1004.2
03:48 ET10094.195
03:50 ET3004.2
03:52 ET19484.22
03:54 ET39424.22
03:56 ET4004.215
03:57 ET19434.225
03:59 ET597374.23
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMGTX
MeiraGTx Holdings PLC
320.3M
-2.8x
---
United StatesITOS
Iteos Therapeutics Inc
365.2M
-3.3x
---
United StatesXOMA
XOMA Royalty Corp
317.7M
-12.3x
---
United StatesCRVS
Corvus Pharmaceuticals Inc
318.4M
-11.8x
---
United StatesGLUE
Monte Rosa Therapeutics Inc
325.3M
-2.4x
---
United StatesINZY
Inozyme Pharma Inc
314.9M
-3.5x
---
As of 2024-10-03

Company Information

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Contact Information

Headquarters
450 E 29th St Fl 15NEW YORK, NY, United States 10016-8367
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Keith Harris
President, Chief Executive Officer, Director
Alexandria Forbes
Chief Financial Officer, Chief Operating Officer
Richard Giroux
General Counsel, Secretary
Robert Wollin
Chief Development Officer
Stuart Naylor

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$326.5M
Revenue (TTM)
$8.1M
Shares Outstanding
77.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.29
EPS
$-1.49
Book Value
$2.17
P/E Ratio
-2.8x
Price/Sales (TTM)
40.2
Price/Cash Flow (TTM)
---
Operating Margin
-2,083.19%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.